CompletedNot Applicable

Memory Perception Assessment in Central/Non-central Nervous System Cancers

France426 participantsStarted 2019-05-10

Plain-language summary

Prospective memory (PM) is the ability to implement intended actions in the future. It allows maintaining and retrieving future plans, goals, and activities (i.e., remember to remember). PM is associated with most everyday memory problems . PM is crucial to correctly respond to all the social, occupational and working demands of everyday life, to perform many deferred health-related actions and is involved in therapeutic adherence . Indeed, PM errors are an important part of the aging memory complaints. The prevalence of self-reported PM failures is also significant among young adults, compared with self-reported retrospective memory (RM) failures .Yet, PM errors are major sources of frustration and embarrassment . In oncology, recently investigated the self-reported memory complaints in a 80 case-healthy-control study breast patients . Subjective memory complaints were assessed using the Prospective and Retrospective Memory Questionnaire . Results from the Paquet et al. study show that all participants (i.e., both patients and matched-controls) reported more PM than RM failures in daily-life (p\<.001). Breast cancer patients reported more RM and PM failures than controls. However, this group effect was no longer statistically significant when controlling for depression and fatigue. These findings are consistent with the view that memory complaints are closely associated with depression and cancer-related fatigue, and more generally with psychopathological variables .As underlined by Paquet et al. subjective memory complaints should be investigated because they refer to some aspects of the cancer experience that could potentially be linked to quality of life. Thus, it is important to explore psychopathological basis such as depression, anxiety and fatigue while investigating self-reported memory failures in cancer patients. Despites the importance of PM, there have been, to our knowledge, only few studies evaluating PM complaints or PM functioning in patients diagnosed with an intracerebral tumor (such as Diffuse Low-Grade Glioma- DLGG- or glioblastome- GB) or extra-cerebral tumor (such as breast cancer - BC). Therefore, the investigators thought it would be useful, as a first step, to conduct a study to explore and to manage the PM and RM subjective complaints in cancer patients compared to another chronic disease, such as HIV. In fine, these data will help to identify a new target for psychological management focused on either psychopathological or neuropsychological rehabilitation

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: All the participants must fulfill all the following criteria to be eligible for study entry: * Be aged of 18 to 80 years old * Have a ECOG Performance Status ≤ 2 or a Karnofsky index ≥ 50 % * Have a satisfactory level of French * Have signed the informed consent Also, for the DLGG group, the patients must: * Have a histologically-proven diagnosis of DLGG (i.e., WHO grade II glioma) * Receive or have received a first oncological treatment after surgery (chemotherapy, radiation therapy…) Also, for the GB group, the patients must: \- Have a histologically-proven diagnosis of GB (i.e., WHO grade IV glioma). Also, for the breast cancer group, the patients must: \- Have a histologically-proven diagnosis of breast cancer diagnosed \< 2 years. Exclusion Criteria: Participants presenting with any of the following exclusion criteria will not be included in the study: * Patients with brain metastases * Patients under tutorship or curatorship or protective measures * Patients suffering from sensorial or motor deficits avoiding the tests administration * Patients with a reported history of psychiatric disease (e.g., mental retardation, psychotic disorders, learning disabilities, attention-deficit/hyperactivity disorder, and bipolar disorder) * Have reported a substance dependence within the past six months (e.g., cocaine or methamphetamine dependence) * Pregnant women * Legal incapacity or physical, psychological social or geographical status interfering wit…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial studied 'subjective memory complaints' in people with glioblastoma or glioma — what does that mean in practice, and could it help explain the memory or thinking changes I've been noticing since my diagnosis?
2Since this trial has already been completed, has my doctor seen or can they access any findings from it that might be relevant to how we monitor my cognitive health going forward?
3The trial also included people with breast cancer and healthy volunteers as comparison groups — does that tell us something useful about how brain tumors specifically affect memory perception differently from other cancers?
4Given that this was an observational study measuring memory complaints rather than testing a treatment, how would my doctor use insights from this kind of research to actually change or guide my care?
5Are there any follow-up studies or active trials building on this research that might offer me a more direct benefit, especially around managing cognitive symptoms related to my diagnosis?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

the nature of subjective memory complaints

Timeframe: 12 months

Trial details

NCT IDNCT03975959

SponsorInstitut du Cancer de Montpellier - Val d'Aurelle

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-27

View on ClinicalTrials.gov More Glioblastoma trials